Overview

The central theme of my research program, Pharmaceutical Outcomes and Policy Innovations (POPi), is the study of drug therapy with the goal of improving human health and quality of life.

I am particularly interested in developing models for evaluating drug effectiveness, medication use models designed to improve patient health, and effective surveillance systems to improve the safe use of medication.

I have a particular clinical interest in pediatric medicine, with specific emphases on asthma and the epidemiology and clinical management of adverse drug reactions.

Another area of interest is the translation of knowledge to aid evidence-based drug policy development. POPi contributes to solving the international drug policy crisis on two levels: the public policy level (federal and provincial), and the clinical policy level. In this way the needs of government are served to manage drug budgets, the needs of clinicians to improve patient care, and the public need to understand and improve the effectiveness, safety and cost effectiveness of drugs.

Publications

Further investigation of the role of ACYP2 and WFS1 pharmacogenomic variants in the development of cisplatin-induced ototoxicity in testicular cancer patients.
Clinical cancer research : an official journal of the American Association for Cancer Research
Drögemöller BI and Brooks B and Monzon JG and Wright GE and Liu G and Renouf DJ and Kollmannsberger C and Bedard PL and Hayden MR and Gelmon KA and Carleton B and Ross CJ
DOI: 10.1158/1078-0432.ccr-17-2810
PubMed: 29358504
01/2018

An initial health economic evaluation of pharmacogenomic testing in patients treated for childhood cancer with anthracyclines.
Pediatric blood & cancer
Dionne F and Aminkeng F and Bhavsar AP and Groeneweg G and Smith A and Visscher H and Rassekh SR and Ross C and Carleton B
DOI: 10.1002/pbc.26887
PubMed: 29271558
03/2018

Assessment of hair cortisol as a potential biomarker for possible adrenal suppression due to inhaled corticosteroid use in children with asthma: A retrospective observational study.
Clinical biochemistry
Smy L and Shaw K and Amstutz U and Staub M and Chaudhry S and Smith A and Carleton B and Koren G
DOI: 10.1016/j.clinbiochem.2018.04.006
PubMed: 29673814
04/2018

Pharmacogenetic variants in TPMT alter cellular responses to cisplatin in inner ear cell lines.
PloS one
Bhavsar AP and Gunaretnam EP and Li Y and Hasbullah JS and Carleton BC and Ross CJ
DOI: 10.1371/journal.pone.0175711
PubMed: 28406961
2017

Association Between SLC16A5 Genetic Variation and Cisplatin-Induced Ototoxic Effects in Adult Patients With Testicular Cancer.
JAMA oncology
Drögemöller BI and Monzon JG and Bhavsar AP and Borrie AE and Brooks B and Wright GEB and Liu G and Renouf DJ and Kollmannsberger CK and Bedard PL and Aminkeng F and Amstutz U and Carleton BC
DOI: 10.1001/jamaoncol.2017.0502
PubMed: 28448657
11/2017

Recommendations for Genetic Testing to Reduce the Incidence of Anthracycline-induced Cardiotoxicity.
Aminkeng F and Ross CJ and Rassekh SR and Hwang S and Rieder MJ and Bhavsar AP and Smith A and Sanatani S and Gelmon KA and Bernstein D and Hayden MR and Amstutz U and Carleton BC and CPNDS Clinical Practice Recommendations Group
DOI: 10.1111/bcp.13008
PubMed: 27197003
05/2016

A coding variant in RARG confers susceptibility to anthracycline-induced cardiotoxicity in childhood cancer.
Aminkeng F and Bhavsar AP and Visscher H and Rassekh SR and Li Y and Lee JW and Brunham LR and Caron HN and van Dalen EC and Kremer LC and van der Pal HJ and Amstutz U and Rieder MJ and Bernstein D and Carleton BC and Hayden MR and Ross CJ and Canadian Pharmacogenomics Network for Drug Safety Consortium
DOI: 10.1038/ng.3374
PubMed: 26237429
09/2015

Recommendations for HLA-B*15:02 and HLA-A*31:01 genetic testing to reduce the risk of carbamazepine-induced hypersensitivity reactions.
Amstutz U and Shear NH and Rieder MJ and Hwang S and Fung V and Nakamura H and Connolly MB and Ito S and Carleton BC and CPNDS clinical recommendation group
DOI: 10.1111/epi.12564
PubMed: 24597466
04/2014

Economic impact of a genetic test for cisplatin-induced ototoxicity.
Dionne F and Mitton C and Rassekh R and Brooks B and Ross C and Hayden M and Carleton B
DOI: 10.1038/tpj.2011.15
PubMed: 21502965
06/2012

The Canadian Pharmacogenomics Network for Drug Safety: a model for safety pharmacology.
Ross CJ and Visscher H and Sistonen J and Brunham LR and Pussegoda K and Loo TT and Rieder MJ and Koren G and Carleton BC and Hayden MR and CPNDS Consortium
DOI: 10.1089/thy.2010.1642
PubMed: 20578893
07/2010

Analyses of Adverse Drug Reactions-Nationwide Active Surveillance Network: Canadian Pharmacogenomics Network for Drug Safety Database.
Journal of clinical pharmacology
Tanoshima R and Khan A and Biala AK and Trueman JN and Drögemöller BI and Wright GEB and Hasbullah JS and Groeneweg GSS and Ross CJD and Carleton BC and Canadian Pharmacogenomics Network for Drug Safety Consortium
DOI: 10.1002/jcph.1336
PubMed: 30452777
11/2018

The incidence of symptomatic osteonecrosis after allogeneic haematopoietic stem cell transplantation in children with acute lymphoblastic leukaemia - controversy on dexamethasone as a risk factor.
British journal of haematology
Tanoshima R and Carleton BC
DOI: 10.1111/bjh.15657
PubMed: 30408145
11/2018

CYP2D6 as a treatment decision aid for ER-positive non-metastatic breast cancer patients: a systematic review with accompanying clinical practice guidelines.
Breast cancer research and treatment
Drögemöller BI and Wright GEB and Shih J and Monzon JG and Gelmon KA and Ross CJD and Amstutz U and Carleton BC and CPNDS Clinical Recommendations Group
DOI: 10.1007/s10549-018-5027-0
PubMed: 30411242
11/2018

Incidence rates of narcolepsy diagnoses in Taiwan, Canada, and Europe: The use of statistical simulation to evaluate methods for the rapid assessment of potential safety issues on a population level in the SOMNIA study.
PloS one
Dodd CN and de Ridder M and Huang WT and Weibel D and Giner-Soriano M and Perez-Vilar S and Diez-Domingo J and Svenson LW and Mahmud SM and Carleton B and Naus M and Kwong JC and Sturkenboom M
DOI: 10.1371/journal.pone.0204799
PubMed: 30332477
10/2018

Antipsychotic-Associated Symptoms of Tourette Syndrome: A Systematic Review.
CNS drugs
Kim DD and Barr AM and Chung Y and Yuen JWY and Etminan M and Carleton BC and White RF and Honer WG and Procyshyn RM
DOI: 10.1007/s40263-018-0559-8
PubMed: 30121819
10/2018

Tumor necrosis factor inhibitors and risk of peripheral neuropathy in patients with rheumatic diseases.
Seminars in arthritis and rheumatism
Etminan M and Sodhi M and Samii A and Carleton BC and Kezouh A and Antonio Avina-Zubieta J
DOI: 10.1016/j.semarthrit.2018.09.006
PubMed: 30337056
09/2018

Reducing anthracycline-induced cardiotoxicity through pharmacogenetics.
Pharmacogenomics
Scott E and Hasbullah JS and Ross CJ and Carleton BC
DOI: 10.2217/pgs-2018-0124
PubMed: 30213233
09/2018

Oral fluoroquinolones and risk of fibromyalgia.
British journal of clinical pharmacology
Ganjizadeh-Zavareh S and Sodhi M and Spangehl T and Carleton B and Etminan M
DOI: 10.1111/bcp.13765
PubMed: 30216492
09/2018

Genetic Variations and Cisplatin Nephrotoxicity: A Systematic Review.
Frontiers in pharmacology
Zazuli Z and Vijverberg S and Slob E and Liu G and Carleton B and Veltman J and Baas P and Masereeuw R and Maitland-van der Zee AH
DOI: 10.3389/fphar.2018.01111
PubMed: 30319427
09/2018

Association of Antidepressant Use With Drug-Related Extrapyramidal Symptoms: A Pharmacoepidemiological Study.
Journal of clinical psychopharmacology
Guo MY and Etminan M and Procyshyn RM and Kim DD and Samii A and Kezouh A and Carleton BC
DOI: 10.1097/jcp.0000000000000911
PubMed: 29901567
08/2018

In Reply to Controversies on the Use of Glaucoma Medications During Surgery.
Journal of glaucoma
Wendel C and Zakrzewski H and Carleton B and Etminan M and Mikelberg FS
DOI: 10.1097/ijg.0000000000001074
PubMed: 30180014
08/2018

Narcolepsy and adjuvanted pandemic influenza A (H1N1) 2009 vaccines - Multi-country assessment.
Vaccine
Weibel D and Sturkenboom M and Black S and de Ridder M and Dodd C and Bonhoeffer J and Vanrolleghem A and van der Maas N and Lammers GJ and Overeem S and Gentile A and Giglio N and Shimabukuro TT
DOI: 10.1016/j.vaccine.2018.08.008
PubMed: 30122647
08/2018

Common variation near IRF6 is associated with IFN-ß-induced liver injury in multiple sclerosis.
Nature genetics
Kowalec K and Wright GEB and Drögemöller BI and Aminkeng F and Bhavsar AP and Kingwell E and Yoshida EM and Traboulsee A and Marrie RA and Kremenchutzky M and Campbell TL and Carleton BC
DOI: 10.1038/s41588-018-0168-y
PubMed: 30013178
07/2018

Pharmacogenomics of Vincristine-Induced Peripheral Neuropathy Implicates Pharmacokinetic and Inherited Neuropathy Genes.
Clinical pharmacology and therapeutics
Wright GEB and Amstutz U and Drögemöller BI and Shih J and Rassekh SR and Hayden MR and Carleton BC and Ross CJD and Canadian Pharmacogenomics Network for Drug Safety Consortium
DOI: 10.1002/cpt.1179
PubMed: 29999516
07/2018

Statin medications and the risk of gynecomastia.
Clinical endocrinology
Skeldon SC and Carleton B and Brophy JM and Sodhi M and Etminan M
DOI: 10.1111/cen.13794
PubMed: 29923212
07/2018

HUME: Large-scale Detection of Causal Genetic Factors of Adverse Drug Reactions.
Bioinformatics (Oxford, England)
Mansouri M and Yuan B and Ross CJD and Carleton BC and Ester M
DOI: 10.1093/bioinformatics/bty475
PubMed: 29931042
06/2018

Activated protein C as disease-modifying therapy in antenatal preeclampsia: An open-label, single arm safety and efficacy trial.
Pregnancy hypertension
von Dadelszen P and Magee LA and Benton SJ and Hu Y and Ansermino JM and Carleton B and Carter C and Douglas MJ and Janssen PA and Lee SK and Leung PCK and Li J and MacNab Y and Payne BA and Russell JA
DOI: 10.1016/j.preghy.2018.05.009
PubMed: 30177038
05/2018

Oral Fluoroquinolone Prescribing to Children in the United States From 2006 to 2015.
The Pediatric infectious disease journal
Etminan M and Guo M and Carleton B
DOI: 10.1097/inf.0000000000002121
PubMed: 29846302
05/2018

The influence of genetic variation on late toxicities in childhood cancer survivors: A review.
Critical reviews in oncology/hematology
Clemens E and van der Kooi ALF and Broer L and van Dulmen-den Broeder E and Visscher H and Kremer L and Tissing W and Loonen J and Ronckers CM and Pluijm SMF and Neggers SJCMM and van den Heuvel-Eibrink MM
DOI: 10.1016/j.critrevonc.2018.04.001
PubMed: 29759558
04/2018

Response to The routine use of oral steroids in paediatric asthma is not routine.
Paediatrics & child health
Smith N and Wang A and Shaw K and Groeneweg G and Goldman RD and Wilkinson B and Jimenez R and Mwai L and Carleton B
DOI: 10.1093/pch/pxy006
PubMed: 29769812
04/2018

Risk of Anterior Segment Complications Associated With the Live Herpes Zoster Vaccine: Evidence From a Health-Claim Database.
Cornea
Liu RT and Yeung SN and Carleton B and Etminan M
DOI: 10.1097/ico.0000000000001595
PubMed: 29601366
03/2018

Association of Post-operative Topical Prostaglandin Analog or Beta-blocker Use and Incidence of Pseudophakic Cystoid Macular Edema.
Journal of glaucoma
Wendel C and Zakrzewski H and Carleton B and Etminan M and Mikelberg FS
DOI: 10.1097/ijg.0000000000000929
PubMed: 29505438
03/2018

Clinical Pharmacogenetics Implementation Consortium Guideline for HLA Genotype and Use of Carbamazepine and Oxcarbazepine: 2017 Update.
Clinical pharmacology and therapeutics
Phillips EJ and Sukasem C and Whirl-Carrillo M and Müller DJ and Dunnenberger HM and Chantratita W and Goldspiel B and Chen YT and Carleton BC and George AL and Mushiroda T and Pirmohamed M
DOI: 10.1002/cpt.1004
PubMed: 29392710
02/2018

Genetic variation in CFH predicts phenytoin-induced maculopapular exanthema in European-descent patients.
Neurology
McCormack M and Gui H and Ingason A and Speed D and Wright GEB and Zhang EJ and Secolin R and Yasuda C and Kwok M and Wolking S and Becker F and Rau S and Avbersek A and Heggeli K and Leu C and Cavalleri GL
DOI: 10.1212/wnl.0000000000004853
PubMed: 29288229
01/2018

Risk of hair loss with different antidepressants: a comparative retrospective cohort study.
International clinical psychopharmacology
Etminan M and Sodhi M and Procyshyn RM and Guo M and Carleton BC
DOI: 10.1097/yic.0000000000000191
PubMed: 28763345
01/2018

SJS/TEN 2017: Building Multidisciplinary Networks to Drive Science and Translation.
The journal of allergy and clinical immunology. In practice
White KD and Abe R and Ardern-Jones M and Beachkofsky T and Bouchard C and Carleton B and Chodosh J and Cibotti R and Davis R and Denny JC and Dodiuk-Gad RP and Ergen EN and Goldman JL and Phillips EJ
DOI: 10.1016/j.jaip.2017.11.023
PubMed: 29310768
2018

Pharmacogenomic Variability of Oral Baclofen Clearance and Clinical Response in Children With Cerebral Palsy.
PM & R : the journal of injury, function, and rehabilitation
McLaughlin MJ and He Y and Brunstrom-Hernandez J and Thio LL and Carleton BC and Ross CJD and Gaedigk A and Lewandowski A and Dai H and Jusko WJ and Leeder JS
DOI: 10.1016/j.pmrj.2017.08.441
PubMed: 28867665
09/2017

Dentists’ Prescribing of Analgesics for Children in British Columbia, Canada
Journal (Canadian Dental Association)
Etminan M and Nouri MR and Sodhi M and Carleton BC
PubMed: 29360020
08/2017

Fluoroquinolone Use and Risk of Carpal Tunnel Syndrome: A Pharmacoepidemiologic Study.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
Cheng JZ and Sodhi M and Etminan M and Carleton BC
DOI: 10.1093/cid/cix362
PubMed: 28444196
08/2017

Oral fluoroquinolones and risk of secondary pseudotumor cerebri syndrome: Nested case-control study.
Neurology
Sodhi M and Sheldon CA and Carleton B and Etminan M
DOI: 10.1212/wnl.0000000000004247
PubMed: 28754842
08/2017

Rationale and design of the multiethnic Pharmacogenomics in Childhood Asthma consortium.
Pharmacogenomics
Farzan N and Vijverberg SJ and Andiappan AK and Arianto L and Berce V and Blanca-López N and Bisgaard H and Bønnelykke K and Burchard EG and Campo P and Canino G and Carleton B and Maitland-van der Zee AH
DOI: 10.2217/pgs-2017-0035
PubMed: 28639505
07/2017

Physician and parent barriers to the use of oral corticosteroids for the prevention of paediatric URTI-induced acute asthma exacerbations at home.
Paediatrics & child health
Smith N and Smith A and Wang A and Shaw K and Groeneweg G and Goldman RD and Wilkinson B and Jimenez R and Mwai L and Carleton B
DOI: 10.1093/pch/pxx047
PubMed: 29479212
07/2017

Improved strength on 5-hydroxytryptophan and carbidopa in spinal cord atrophy.
Journal of the neurological sciences
Horvath GA and Meisner L and Selby K and Stowe R and Carleton B
DOI: 10.1016/j.jns.2017.04.047
PubMed: 28566180
07/2017

Application of pharmacogenomics to investigate adverse drug reactions to the disease-modifying treatments for multiple sclerosis: a case-control study protocol for dimethyl fumarate-induced lymphopenia.
BMJ open
Kowalec K and Kingwell E and Carruthers R and Marrie RA and Bernatsky S and Traboulsee A and Ross CJD and Carleton B and Tremlett H
DOI: 10.1136/bmjopen-2017-016276
PubMed: 28576902
06/2017

Pharmacogenomic screening for anthracycline-induced cardiotoxicity in childhood cancer.
British journal of clinical pharmacology
Aminkeng F and Ross CJD and Rassekh SR and Rieder MJ and Bhavsar AP and Sanatani S and Bernstein D and Hayden MR and Amstutz U and Carleton BC
DOI: 10.1111/bcp.13218
PubMed: 28317142
05/2017

Association of Repeated Intravitreous Bevacizumab Injections With Risk for Glaucoma Surgery.
JAMA ophthalmology
Eadie BD and Etminan M and Carleton BC and Maberley DA and Mikelberg FS
DOI: 10.1001/jamaophthalmol.2017.0059
PubMed: 28301639
04/2017

Design and Methods of the Pan-Canadian Applying Biomarkers to Minimize Long-Term Effects of Childhood/Adolescent Cancer Treatment (ABLE) Nephrotoxicity Study: A Prospective Observational Cohort Study.
Canadian journal of kidney health and disease
McMahon KR and Rod Rassekh S and Schultz KR and Pinsk M and Blydt-Hansen T and Mammen C and Tsuyuki RT and Devarajan P and Cuvelier GD and Mitchell LG and Baruchel S and Palijan A and Applying Biomarkers to Minimize Long-Term Effects of Childhood/Adolescent Cancer Treatment (ABLE) Research Group
DOI: 10.1177/2054358117690338
PubMed: 28270931
2017

Risk of Gambling Disorder and Impulse Control Disorder With Aripiprazole, Pramipexole, and Ropinirole: A Pharmacoepidemiologic Study.
Etminan M and Sodhi M and Samii A and Procyshyn RM and Guo M and Carleton BC
PubMed: 27930495
12/2016

Oral morphine dosing predictions based on single dose in healthy children undergoing surgery.
Dawes JM and Cooke EM and Hannam JA and Brand KA and Winton P and Jimenez-Mendez R and Aleksa K and Lauder GR and Carleton BC and Koren G and Rieder MJ and Anderson BJ and Montgomery CJ
DOI: 10.1111/pan.13020
PubMed: 27779356
10/2016

Risk of Extrapyramidal Adverse Events With Aripiprazole.
Etminan M and Procyshyn RM and Samii A and Carleton BC
DOI: 10.1097/jcp.0000000000000543
PubMed: 27580493
10/2016

The global spectrum of protein-coding pharmacogenomic diversity.
Wright GE and Carleton B and Hayden MR and Ross CJ
DOI: 10.1038/tpj.2016.77
PubMed: 27779249
10/2016

Risk of sensorineural hearing loss with macrolide antibiotics: A nested case-control study.
Etminan M and Westerberg BD and Kozak FK and Guo MY and Carleton BC
PubMed: 27497265
08/2016

An in silico framework for integrating epidemiologic and genetic evidence with health care applications: ventilation-related pneumothorax as a case illustration.
Torosyan Y and Hu Y and Hoffman S and Luo Q and Carleton B and Marinac-Dabic D
DOI: 10.1093/jamia/ocw031
PubMed: 27107435
07/2016

Asthma in British Columbia: Are We Finally Breathing Easier? A population based study of the burden of disease Over 14 Years.
Bardal S and Smith A and Luo HA and Zhang T and Groeneweg G and Jimenez Mendez R and Goldman R and Carleton B
PubMed: 27414432
07/2016

Risk of Myocardial Infarction and Stroke With Single or Repeated Doses of Intravitreal Bevacizumab in Age-Related Macular Degeneration.
Etminan M and Maberley DA and Babiuk DW and Carleton BC
DOI: 10.1016/j.ajo.2016.03.026
PubMed: 27093892
06/2016

Pharmacogenomics in Pediatric Patients: Towards Personalized Medicine.
Maagdenberg H and Vijverberg SJ and Bierings MB and Carleton BC and Arets HG and de Boer A and Maitland-van der Zee AH
PubMed: 27142473
05/2016

Clinical Practice Recommendations For The Management And Prevention Of Cisplatin-Induced Hearing Loss Using Pharmacogenetic Markers.
Lee JW and Pussegoda K and Rassekh RS and Monzon JG and Liu G and Hwang S and Bhavsar AP and Pritchard S and Ross CJ and Amstutz U and Carleton BC and CPNDS clinical recommendations group
PubMed: 26960170
03/2016

Risk of Myocardial Infarction and Stroke With Single or Repeated Doses of Intravitreal Bevacizumab in Age-Related Macular Degeneration.
Etminan M and Maberley DA and Babiuk DW and Carleton BC
DOI: 10.1016/j.ajo.2015.11.030
PubMed: 26701272
03/2016

Genetic diversity of variants involved in drug response and metabolism in Sri Lankan populations: implications for clinical implementation of pharmacogenomics.
Chan SL and Samaranayake N and Ross CJ and Toh MT and Carleton B and Hayden MR and Teo YY and Dissanayake VH and Brunham LR
DOI: 10.1097/FPC.0000000000000182
PubMed: 26444257
01/2016

Hair cortisol as a hypothalamic-pituitary-adrenal axis biomarker in pregnant women with asthma: a retrospective observational study.
Smy L and Shaw K and Amstutz U and Smith A and Berger H and Carleton B and Koren G
DOI: 10.1186/s12884-016-0962-4
PubMed: 27440139
2016

Risperidone and Risk of Gynecomastia in Young Men.
Etminan M and Carleton B and Brophy JM
DOI: 10.1089/cap.2015.0024
PubMed: 26287371
11/2015

A Compartmental Analysis for Morphine and Its Metabolites in Young Children After a Single Oral Dose.
Velez de Mendizabal N and Jimenez-Mendez R and Cooke E and Montgomery CJ and Dawes J and Rieder MJ and Aleksa K and Koren G and Jacobo-Cabral CO and Gonzalez-Ramirez R and Castañeda-Hernandez G and Carleton BC
DOI: 10.1007/s40262-015-0256-4
PubMed: 25773480
10/2015

The pharmacogenetics of codeine pain relief in the postpartum period.
Baber M and Chaudhry S and Kelly L and Ross C and Carleton B and Berger H and Koren G
DOI: 10.1038/tpj.2015.3
PubMed: 25752520
10/2015

Clinical Practice Recommendations on Genetic Testing of CYP2C9 and VKORC1 Variants in Warfarin Therapy.
Shaw K and Amstutz U and Kim RB and Lesko LJ and Turgeon J and Michaud V and Hwang S and Ito S and Ross C and Carleton BC and CPNDS Clinical Recommendation Group
DOI: 10.1097/FTD.0000000000000192
PubMed: 26186657
08/2015

Cisplatin Nephrotoxicity and Longitudinal Growth in Children With Solid Tumors: A Retrospective Cohort Study.
Jiménez-Triana CA and Castelán-Martínez OD and Rivas-Ruiz R and Jiménez-Méndez R and Medina A and Clark P and Rassekh R and Castañeda-Hernández G and Carleton B and Medeiros M and Canadian Pharmacogenomics Network for Drug Safety Consortium
DOI: 10.1097/MD.0000000000001413
PubMed: 26313789
08/2015

Hair cortisol as a novel biomarker of HPA suppression by inhaled corticosteroids in children.
Smy L and Shaw K and Smith A and Russell E and Van Uum S and Rieder M and Carleton B and Koren G
DOI: 10.1038/pr.2015.60
PubMed: 25790275
07/2015

Association between regulatory advisories and codeine prescribing to postpartum women.
Smolina K and Weymann D and Morgan S and Ross C and Carleton B
DOI: 10.1001/jama.2015.3642
PubMed: 25965237
05/2015

Post-renal transplant erythrocytosis: a case report.
Almonte M and Velásquez-Jones L and Valverde S and Carleton B and Medeiros M
DOI: 10.1111/petr.12406
PubMed: 25418869
02/2015

Testosterone therapy and risk of myocardial infarction: a pharmacoepidemiologic study.
Etminan M and Skeldon SC and Goldenberg SL and Carleton B and Brophy JM
DOI: 10.1002/phar.1534
PubMed: 25582846
01/2015

Integrating Personalized Medicine in the Canadian Environment: Efforts Facilitating Oncology Clinical Research.
Syme R and Carleton B and Leyens L and Richer E
DOI: 10.1159/000441560
PubMed: 26565702
2015

New Ways of Detecting ADRs in Neonates and Children.
Jimenez R and Smith A and Carleton B
PubMed: 26323415
2015

Genetic variants in SLC22A17 and SLC22A7 are associated with anthracycline-induced cardiotoxicity in children.
Visscher H and Rassekh SR and Sandor GS and Caron HN and van Dalen EC and Kremer LC and van der Pal HJ and Rogers PC and Rieder MJ and Carleton BC and Hayden MR and Ross CJ and CPNDS consortium
DOI: 10.2217/pgs.15.61
PubMed: 26230641
2015

Genetic determinants of cocaine-associated agranulocytosis.
Buxton JA and Omura J and Kuo M and Ross C and Tzemis D and Purssell R and Gardy J and Carleton B
DOI: 10.1186/s13104-015-1219-4
PubMed: 26070312
2015

Use of pharmacogenomics in pediatric renal transplant recipients.
Medeiros M and Castañeda-Hernández G and Ross CJ and Carleton BC
DOI: 10.3389/fgene.2015.00041
PubMed: 25741362
2015

Pharmacogenomic diversity in Singaporean populations and Europeans.
Brunham LR and Chan SL and Li R and Aminkeng F and Liu X and Saw WY and Ong RT and Pillai EN and Carleton BC and Toh D and Tan SH and Koo SH and Lee EJ and Chia KS and Ross CJ and Hayden MR and Sung C and Teo YY
DOI: 10.1038/tpj.2014.22
PubMed: 24861855
12/2014

Emergency department visits for children with acute asthma: discharge instructions, parental plans, and follow-through of care--a prospective study.
Camp PG and Norton SP and Goldman RD and Shajari S and Smith MA and Heathcote S and Carleton B
PubMed: 25358278
11/2014

Risperidone use and risk for gynecomastia in men.
Etminan M and Heran B and Carleton B and Brophy JM
DOI: 10.1097/JCP.0000000000000182
PubMed: 25006814
10/2014

Characteristics associated with drug-induced liver injury from interferon beta in multiple sclerosis patients.
Kowalec K and Kingwell E and Yoshida EM and Marrie RA and Kremenchutzky M and Campbell TL and Wadelius M and Carleton B and Tremlett H
DOI: 10.1517/14740338.2014.947958
PubMed: 25134421
10/2014

Genetic markers of cisplatin-induced hearing loss in children.
Carleton BC and Ross CJ and Pussegoda K and Bhavsar AP and Visscher H and Lee JW and Brooks B and Rassekh SR and Dubé MP and Hayden MR
DOI: 10.1038/clpt.2014.92
PubMed: 25141953
09/2014

Hearing loss in Mexican children treated with cisplatin.
Castelán-Martínez OD and Jiménez-Méndez R and Rodríguez-Islas F and Fierro-Evans M and Vázquez-Gómez BE and Medina-Sansón A and Clark P and Carleton B and Ross C and Hildebrand C and Castañeda-Hernández G and Rivas-Ruiz R
DOI: 10.1016/j.ijporl.2014.06.007
PubMed: 25037447
09/2014

Response to "evaluation of pharmacogenetic markers to predict the risk of Cisplatin-induced ototoxicity".
Carleton BC and Ross CJ and Bhavsar AP and Lee JW and Visscher H and Rassekh SR and Hayden MR
DOI: 10.1038/clpt.2014.90
PubMed: 24755913
08/2014

The emerging era of pharmacogenomics: current successes, future potential, and challenges.
Lee JW and Aminkeng F and Bhavsar AP and Shaw K and Carleton BC and Hayden MR and Ross CJ
DOI: 10.1111/cge.12392
PubMed: 24684508
07/2014

Development of a broad-based ADME panel for use in pharmacogenomic studies.
Brown AM and Renaud Y and Ross C and Hansen M and Mongrain I and Valois D and Carleton BC and Hayden MR and Dubé MP and Tardif JC and Phillips MS
DOI: 10.2217/pgs.14.81
PubMed: 25141894
06/2014

VKORC1 and CYP2C9 genotypes are predictors of warfarin-related outcomes in children.
Shaw K and Amstutz U and Hildebrand C and Rassekh SR and Hosking M and Neville K and Leeder JS and Hayden MR and Ross CJ and Carleton BC
DOI: 10.1002/pbc.24932
PubMed: 24474498
06/2014

Rising antipsychotic prescriptions for children and youth: cross-sectoral solutions for a multimodal problem.
Di Pietro N and Illes J and Canadian Working Group on Antipsychotic Medications and Children
DOI: 10.1503/cmaj.131604
PubMed: 24664655
06/2014

Codeine-related deaths: The role of pharmacogenetics and drug interactions.
Lam J and Woodall KL and Solbeck P and Ross CJ and Carleton BC and Hayden MR and Koren G and Madadi P
DOI: 10.1016/j.forsciint.2014.03.018
PubMed: 24747667
06/2014

Public perceptions of pharmacogenetics.
Zhang SC and Bruce C and Hayden M and Rieder MJ
DOI: 10.1542/peds.2013-1416
PubMed: 24777223
05/2014

Higher frequency of genetic variants conferring increased risk for ADRs for commonly used drugs treating cancer, AIDS and tuberculosis in persons of African descent.
Aminkeng F and Ross CJ and Rassekh SR and Brunham LR and Sistonen J and Dube MP and Ibrahim M and Nyambo TB and Omar SA and Froment A and Bodo JM and Tishkoff S and Carleton BC and Hayden MR and Canadian Pharmacogenomics Network for Drug Safety Consortium
DOI: 10.1038/tpj.2013.13
PubMed: 23588107
04/2014

Role of TPMT and COMT genetic variation in cisplatin-induced ototoxicity.
Carleton BC and Ross CJ and Bhavsar AP and Amstutz U and Pussegoda K and Visscher H and Lee JW and Brooks B and Rassekh SR and Dubé MP and Hayden MR
DOI: 10.1038/clpt.2013.219
PubMed: 24193170
03/2014

Exome sequencing pilot study in children with carbamazepine-induced serious skin reactions.
Amstutz U and Shyr C and Shear NH and Rieder MJ and Wasserman WW and Ross CJ and Carleton BC
DOI: 10.1186/2045-7022-4-S3-P119
2014

Pharmacogenomics and adverse drug reactions in children.
Rieder MJ and Carleton B
DOI: 10.3389/fgene.2014.00078
PubMed: 24795743
2014

Putative association of ABCB1 2677G>T/A with oxycodone-induced central nervous system depression in breastfeeding mothers.
Lam J and Kelly L and Matok I and Ross CJ and Carleton BC and Hayden MR and Madadi P and Koren G
DOI: 10.1097/FTD.0b013e318288f158
PubMed: 23783165
08/2013

Validation of variants in SLC28A3 and UGT1A6 as genetic markers predictive of anthracycline-induced cardiotoxicity in children.
Visscher H and Ross CJ and Rassekh SR and Sandor GS and Caron HN and van Dalen EC and Kremer LC and van der Pal HJ and Rogers PC and Rieder MJ and Carleton BC and Hayden MR and CPNDS Consortium
DOI: 10.1002/pbc.24505
PubMed: 23441093
08/2013

Replication of TPMT and ABCC3 genetic variants highly associated with cisplatin-induced hearing loss in children.
Pussegoda K and Ross CJ and Visscher H and Yazdanpanah M and Brooks B and Rassekh SR and Zada YF and Dubé MP and Carleton BC and Hayden MR and CPNDS Consortium
DOI: 10.1038/clpt.2013.80
PubMed: 23588304
08/2013

High use of health services in patients with suboptimal asthma drug regimens: a population-based assessment in British Columbia, Canada.
Zhang T and Smith MA and Camp PG and Carleton BC
DOI: 10.1002/pds.3444
PubMed: 23559540
07/2013

The potential role of pharmacogenomics in the prevention of serious adverse drug reactions in multiple sclerosis.
Kowalec K and Carleton B and Tremlett H
DOI: 10.1016/j.msard.2012.11.003
PubMed: 25877724
07/2013

HLA-A 31:01 and HLA-B 15:02 as genetic markers for carbamazepine hypersensitivity in children.
Amstutz U and Ross CJ and Castro-Pastrana LI and Rieder MJ and Shear NH and Hayden MR and Carleton BC and CPNDS Consortium
DOI: 10.1038/clpt.2013.55
PubMed: 23588310
07/2013

Cancer pharmacogenomics in children: research initiatives and progress to date.
Rassekh SR and Ross CJ and Carleton BC and Hayden MR
DOI: 10.1007/s40272-013-0021-9
PubMed: 23529868
04/2013

Prescription drug dispensing profiles for one million children: a population-based analysis.
Zhang T and Smith MA and Camp PG and Shajari S and MacLeod SM and Carleton BC
DOI: 10.1007/s00228-012-1343-1
PubMed: 22791273
03/2013

Suspected autoimmune hepatitis and primary biliary cirrhosis unmasked by interferon-beta in a multiple sclerosis patient.
Kowalec K and Yoshida EM and Traboulsee A and Carleton B and Tremlett H
DOI: 10.1016/j.msard.2012.07.004
PubMed: 25877455
01/2013

Clinical practice guideline: CYP2D6 genotyping for safe and efficacious codeine therapy.
Madadi P and Amstutz U and Rieder M and Ito S and Fung V and Hwang S and Turgeon J and Michaud V and Koren G and Carleton BC and CPNDS Clinical Recommendations Group
PubMed: 24214521
2013

A clinical tool for reducing central nervous system depression among neonates exposed to codeine through breast milk.
Kelly LE and Chaudhry SA and Rieder MJ and 't Jong G and Moretti ME and Lausman A and Ross C and Berger H and Carleton B and Hayden MR and Madadi P and Koren G
DOI: 10.1371/journal.pone.0070073
PubMed: 23922910
2013

Physician variability in treating pain and irritability of unknown origin in children with severe neurological impairment.
Siden HB and Carleton BC and Oberlander TF
PubMed: 23885348
2013

Pharmacogenomic investigation of adverse drug reactions(ADRs): the ADR prioritization tool, APT.
Shaw K and Amstutz U and Castro-Pastrana L and Loo TT and Ross CJ and Ito S and Reider MJ and Maher M and Macleod S and Koren G and Hayden MR and Carleton BC
PubMed: 23824325
2013

Life-threatening adverse events following therapeutic opioid administration in adults: is pharmacogenetic analysis useful?
Madadi P and Sistonen J and Silverman G and Gladdy R and Ross CJ and Carleton BC and Carvalho JC and Hayden MR and Koren G
PubMed: 23748253
2013

The use of long-acting ß2- agonists as monotherapy in children and adults.
Camp PG and Zhang T and Smith MA and Carleton BC
PubMed: 23392793
2013

Apnea and oxygen desaturations in children treated with opioids after adenotonsillectomy for obstructive sleep apnea syndrome: a prospective pilot study.
Khetani JD and Madadi P and Sommer DD and Reddy D and Sistonen J and Ross CJ and Carleton BC and Hayden MR and Koren G
DOI: 10.1007/BF03262421
PubMed: 23013460
12/2012

Postpartum maternal codeine therapy and the risk of adverse neonatal outcomes: the devil is in the details.
Lam J and Matlow JN and Ross CJ and Hayden MR and Carleton BC and Madadi P
DOI: 10.1097/FTD.0b013e31825da19f
PubMed: 22777151
08/2012

Differential effect of the rs4149056 variant in SLCO1B1 on myopathy associated with simvastatin and atorvastatin.
Brunham LR and Lansberg PJ and Zhang L and Miao F and Carter C and Hovingh GK and Visscher H and Jukema JW and Stalenhoef AF and Ross CJ and Carleton BC and Kastelein JJ and Hayden MR
DOI: 10.1038/tpj.2010.92
PubMed: 21243006
06/2012

More codeine fatalities after tonsillectomy in North American children.
Kelly LE and Rieder M and van den Anker J and Malkin B and Ross C and Neely MN and Carleton B and Hayden MR and Madadi P and Koren G
DOI: 10.1542/peds.2011-2538
PubMed: 22492761
05/2012

Pharmacogenomic prediction of anthracycline-induced cardiotoxicity in children.
Visscher H and Ross CJ and Rassekh SR and Barhdadi A and Dubé MP and Al-Saloos H and Sandor GS and Caron HN and van Dalen EC and Kremer LC and van der Pal HJ and Brown AM and Rogers PC and Phillips MS and Rieder MJ and Carleton BC and Hayden MR and Canadian Pharmacogenomics Network for Drug Safety Consortium
DOI: 10.1200/JCO.2010.34.3467
PubMed: 21900104
05/2012

Suspected opioid overdose case resolved by CYP2D6 genotyping.
Shaw KD and Amstutz U and Jimenez-Mendez R and Ross CJ and Carleton BC
DOI: 10.1097/FTD.0b013e31824a1e21
PubMed: 22406651
04/2012

Prediction of codeine toxicity in infants and their mothers using a novel combination of maternal genetic markers.
Sistonen J and Madadi P and Ross CJ and Yazdanpanah M and Lee JW and Landsmeer ML and Nauta M and Carleton BC and Koren G and Hayden MR
DOI: 10.1038/clpt.2011.280
PubMed: 22398969
04/2012

Fifty years of pediatric asthma in developed countries: how reliable are the basic data sources?
Chawla J and Seear M and Zhang T and Smith A and Carleton B
DOI: 10.1002/ppul.21537
PubMed: 21905263
03/2012

Central nervous system depression of neonates breastfed by mothers receiving oxycodone for postpartum analgesia.
Lam J and Kelly L and Ciszkowski C and Landsmeer ML and Nauta M and Carleton BC and Hayden MR and Madadi P and Koren G
DOI: 10.1016/j.jpeds.2011.06.050
PubMed: 21880331
01/2012

Beta-blocker use and COPD mortality: a systematic review and meta-analysis.
Etminan M and Jafari S and Carleton B and FitzGerald JM
DOI: 10.1186/1471-2466-12-48
PubMed: 22947076
2012

Using pharmacogenetics to understand adverse drug reactions in children.
Shaw K and Amstutz U and Carleton BC
PubMed: 23115490
11/2011

Pharmacogenomics of cardiovascular drugs and adverse effects in pediatrics.
Visscher H and Amstutz U and Sistonen J and Ross CJ and Hayden MR and Carleton BC
DOI: 10.1097/FJC.0b013e3182163b82
PubMed: 21386709
09/2011

Diagnostic testing for vaccinomics: is the regulatory approval framework adequate? A comparison of Canada, the United States, and Europe.
Joly Y and Koutrikas G and Ramos-Paque E and Zawati M and Gardy J and Hayden MR and Carleton BC
DOI: 10.1089/omi.2010.0135
PubMed: 21728814
09/2011

CYP2D6 polymorphisms and codeine analgesia in postpartum pain management: a pilot study.
VanderVaart S and Berger H and Sistonen J and Madadi P and Matok I and Gijsen VM and de Wildt SN and Taddio A and Ross CJ and Carleton BC and Hayden MR and Koren G
DOI: 10.1097/FTD.0b013e3182272b10
PubMed: 21743374
08/2011

A literature review on distance knowledge exchange in healthcare groups: what can we learn from the ICT literature?
Househ MS and Kushniruk A and Carleton B and Cloutier-Fisher D
DOI: 10.1007/s10916-009-9401-7
PubMed: 20703525
08/2011

Technology enabled knowledge exchange: development of a conceptual framework.
Househ M and Kushniruk A and Cloutier-Fisher D and Carleton B
DOI: 10.1007/s10916-009-9408-0
PubMed: 20703520
08/2011

Phenotype standardization for immune-mediated drug-induced skin injury.
Pirmohamed M and Friedmann PS and Molokhia M and Loke YK and Smith C and Phillips E and La Grenade L and Carleton B and Papaluca-Amati M and Demoly P and Shear NH
DOI: 10.1038/clpt.2011.79
PubMed: 21562486
06/2011

Pharmacogenetic testing: time for clinical practice guidelines.
Amstutz U and Carleton BC
DOI: 10.1038/clpt.2011.18
PubMed: 21508939
06/2011

Sildenafil citrate therapy for severe early-onset intrauterine growth restriction.
von Dadelszen P and Dwinnell S and Magee LA and Carleton BC and Gruslin A and Lee B and Lim KI and Liston RM and Miller SP and Rurak D and Sherlock RL and Skoll MA and Wareing MM and Baker PN and Research into Advanced Fetal Diagnosis and Therapy (RAFT) Group
DOI: 10.1111/j.1471-0528.2010.02879.x
PubMed: 21392225
04/2011

The use of conferencing technologies to support drug policy group knowledge exchange processes: an action case approach.
Househ MS and Kushniruk A and Maclure M and Carleton B and Cloutier-Fisher D
DOI: 10.1016/j.ijmedinf.2010.10.020
PubMed: 21167772
04/2011

Improving pediatric drug safety: need for more efficient clinical translation of pharmacovigilance knowledge.
Castro-Pastrana LI and Carleton BC
PubMed: 21467599
2011

Cutaneous adverse drug reactions in children: an analysis of reports from the Canadian Pharmacogenomics Network for Drug Safety (CPNDS).
Castro-Pastrana LI and Ghannadan R and Rieder MJ and Dahlke E and Hayden M and Carleton B
PubMed: 21467602
2011

The communication of pharmacogenetic research results: participants weigh in on their informational needs in a pilot study.
Madadi P and Joly Y and Avard D and Chitayat DC and Smith MA and D Ross CJ and Carleton BC and Hayden MR and Koren G
PubMed: 21467605
2011

A systematic review of treatment of drug-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in children.
Del Pozzo-Magana BR and Lazo-Langner A and Carleton B and Castro-Pastrana LI and Rieder MJ
PubMed: 21467603
2011

Pharmacogenomics of serious adverse drug reactions in pediatric oncology.
Ross CJ and Visscher H and Rassekh SR and Castro-Pastrana LI and Shereck E and Carleton B and Hayden MR
PubMed: 21467604
2011

Strengths and weaknesses of using conferencing technologies to support drug policy knowledge exchange.
Househ MS and Kushniruk AW and Macclure M and Carleton B and Cloutier-Fisher D
PubMed: 21335744
2011

Regulatory approval for new pharmacogenomic tests: a comparative overview.
Joly Y and Koutrikas G and Tassé AM and Issa A and Carleton B and Hayden M and Rieder MJ and Ramos-Paque E and Avard D
PubMed: 24505844
2011

Demonstrating utility of pharmacogenetics in pediatric populations: methodological considerations.
Carleton B
DOI: 10.1038/clpt.2010.242
PubMed: 21081946
12/2010

Communicating pharmacogenetic research results to breastfeeding mothers taking codeine: a pilot study of perceptions and benefits.
Madadi P and Joly Y and Avard D and Chitayat DC and Smith MA and Ross CJ and Carleton BC and Hayden MR and Koren G
DOI: 10.1038/clpt.2010.125
PubMed: 20739920
12/2010

Fatal hydrocodone overdose in a child: pharmacogenetics and drug interactions.
Madadi P and Hildebrandt D and Gong IY and Schwarz UI and Ciszkowski C and Ross CJ and Sistonen J and Carleton BC and Hayden MR and Lauwers AE and Koren G
DOI: 10.1542/peds.2009-1907
PubMed: 20837591
10/2010

Pharmacogenomics and active surveillance for serious adverse drug reactions in children.
Loo TT and Ross CJ and Sistonen J and Visscher H and Madadi P and Koren G and Hayden MR and Carleton BC
DOI: 10.2217/pgs.10.111
PubMed: 20860467
09/2010

Palivizumab for the prevention of respiratory syncytial virus infection.
Rogovik AL and Carleton B and Solimano A and Goldman RD
PubMed: 20705882
08/2010

Gene-based warfaring dosing.
Carleton B
DOI: 10.1097/FTD.0b013e3181e1a665
PubMed: 20498559
06/2010

Predictive genotype.
Ito S and Carleton BC
DOI: 10.1503/cmaj.110-2061
PubMed: 20479057
05/2010

The comorbidity burden of the treated asthma patient population in British Columbia.
Prosser R and Carleton B and Smith A
PubMed: 20302685
03/2010

Cases: Cocaine adulterant linked to neutropenia.
Wiens MO and Son WK and Ross C and Hayden M and Carleton B
DOI: 10.1503/cmaj.090286
PubMed: 19969562
01/2010

Direct health care costs associated with asthma in British Columbia.
Sadatsafavi M and Lynd L and Marra C and Carleton B and Tan WC and Sullivan S and Fitzgerald JM
PubMed: 20422063
2010

Use of oseltamivir in children.
Jamieson B and Jain R and Carleton B and Goldman RD
PubMed: 20008597
12/2009

The added burden of comorbidity in patients with asthma.
Zhang T and Carleton BC and Prosser RJ and Smith AM
DOI: 10.3109/02770900903350473
PubMed: 19995140
12/2009

Genetic variants in TPMT and COMT are associated with hearing loss in children receiving cisplatin chemotherapy.
Ross CJ and Katzov-Eckert H and Dubé MP and Brooks B and Rassekh SR and Barhdadi A and Feroz-Zada Y and Visscher H and Brown AM and Rieder MJ and Rogers PC and Phillips MS and Carleton BC and Hayden MR and CPNDS Consortium
DOI: 10.1038/ng.478
PubMed: 19898482
12/2009

Application of principal component analysis to pharmacogenomic studies in Canada.
Visscher H and Ross CJ and Dubé MP and Brown AM and Phillips MS and Carleton BC and Hayden MR
DOI: 10.1038/tpj.2009.36
PubMed: 19652663
12/2009

Adverse drug reaction active surveillance: developing a national network in Canada's children's hospitals.
Carleton B and Poole R and Smith M and Leeder J and Ghannadan R and Ross C and Phillips M and Hayden M
DOI: 10.1002/pds.1772
PubMed: 19507171
08/2009

Thiazolidinediones and fractures in men and women.
Dormuth CR and Carney G and Carleton B and Bassett K and Wright JM
DOI: 10.1001/archinternmed.2009.214
PubMed: 19667303
08/2009

Pharmacogenetics of neonatal opioid toxicity following maternal use of codeine during breastfeeding: a case-control study.
Madadi P and Ross CJ and Hayden MR and Carleton BC and Gaedigk A and Leeder JS and Koren G
DOI: 10.1038/clpt.2008.157
PubMed: 18719619
01/2009

A case study examining the impacts of conferencing technologies in distributed healthcare groups.
Househ M and Kushniruk A and Maclure M and Carleton B and Cloutier-Fisher D
PubMed: 20057239
2009

Genotypic Approaches to Therapy in Children (GATC): using information technology to improve drug safety.
Wong E and Carleton BC and Wright DF and Smith MA and Verbeek L and Hildebrand CA and Stannard P and Vaillancourt R and Elliot-Miller P and Ross CJ and Hayden MR
PubMed: 19380938
2009

Drug formulary decision-making in two regional health authorities in British Columbia, Canada.
Armstrong K and Mitton C and Carleton B and Shoveller J
DOI: 10.1016/j.healthpol.2008.04.006
PubMed: 18508151
12/2008

Statin use and the risk of Parkinson disease: a nested case control study.
Samii A and Carleton BC and Etminan M
DOI: 10.1016/j.jocn.2008.01.016
PubMed: 18823780
11/2008

Camouflaged sampling and contacting of people from administrative databases: reaching target patients without knowing who they are.
Maclure M and Warren L and Willison D and Cassels A and Carleton B
DOI: 10.1002/pds.1623
PubMed: 18615549
08/2008

Non-steroidal anti-inflammatory drug use and the risk of Parkinson disease: a retrospective cohort study.
Etminan M and Carleton BC and Samii A
DOI: 10.1016/j.jocn.2007.02.095
PubMed: 18343119
05/2008

Identifying persons with treated asthma using administrative data via latent class modelling.
Prosser RJ and Carleton BC and Smith MA
DOI: 10.1111/j.1475-6773.2007.00775.x
PubMed: 18370976
04/2008

Medication errors: neonates, infants and children are the most vulnerable!
Poole RL and Carleton BC
DOI: 10.5863/1551-6776-13.2.65
PubMed: 23055866
04/2008

Trends in psychostimulant and antidepressant use by children in 2 Canadian provinces.
Mitchell B and Carleton B and Smith A and Prosser R and Brownell M and Kozyrskyj A
PubMed: 18441661
03/2008

Designed delays versus rigorous pragmatic trials: lower carat gold standards can produce relevant drug evaluations.
Maclure M and Carleton B and Schneeweiss S
DOI: 10.1097/MLR.0b013e318068932a
PubMed: 17909382
10/2007

Genotypic approaches to therapy in children: a national active surveillance network (GATC) to study the pharmacogenomics of severe adverse drug reactions in children.
Ross CJ and Carleton B and Warn DG and Stenton SB and Rassekh SR and Hayden MR
DOI: 10.1196/annals.1423.020
PubMed: 17911433
09/2007

Effect of a clinical pathway on the hospitalisation rates of children with asthma: a prospective study.
Norton SP and Pusic MV and Taha F and Heathcote S and Carleton BC
DOI: 10.1136/adc.2006.097287
PubMed: 16905562
01/2007

Pharmacogenomics and its implications for autoimmune disease.
Ross CJ and Katzov H and Carleton B and Hayden MR
DOI: 10.1016/j.jaut.2007.02.008
PubMed: 17418528
2007

Paediatric adverse drug reaction reporting: understanding and future directions.
Carleton BC and Smith MA and Gelin MN and Heathcote SC
PubMed: 17297195
2007

Therapy with both magnesium sulfate and nifedipine does not increase the risk of serious magnesium-related maternal side effects in women with preeclampsia.
Magee LA and Miremadi S and Li J and Cheng C and Ensom MH and Carleton B and Côté AM and von Dadelszen P
DOI: 10.1016/j.ajog.2004.11.059
PubMed: 16021073
07/2005

Formulas containing live probiotic bacteria.
Falk J and Carleton B and Gerber P
PubMed: 15321825
09/2004

Macrolide therapy for Chlamydia pneumoniae in the secondary prevention of coronary artery disease: a meta-analysis of randomized controlled trials.
Etminan M and Carleton B and Delaney JA and Padwal R
DOI: 10.1592/phco.24.4.338.33181
PubMed: 15040646
03/2004

Clinical and economic consequences of a reimbursement restriction of nebulised respiratory therapy in adults: direct comparison of randomised and observational evaluations.
Schneeweiss S and Maclure M and Carleton B and Glynn RJ and Avorn J
DOI: 10.1136/bmj.38020.698194.F6
PubMed: 14982865
03/2004

Quantifying adverse drug events : are systematic reviews the answer?
Etminan M and Carleton B and Rochon PA
DOI: 10.2165/00002018-200427110-00001
PubMed: 15350149
2004

Recognizing idiosyncratic adverse drug reactions in children: A practice imperative.
Carleton B and Primmett D
PubMed: 20084233
04/2001

From professional advocacy to patient advocacy: a gambit for pharmacists.
Carleton BC
PubMed: 11216105
2001

Effects and ethics of sanctions on childhood immunization rates.
Maclure M and Carleton B and Schneeweiss S
DOI: 10.1001/jama.284.16.2056
PubMed: 11042749
10/2000

Evidence-based pharmacotherapy: review of basic concepts and applications in clinical practice.
Etminan M and Wright JM and Carleton BC
DOI: 10.1345/aph.17333
PubMed: 9825086
11/1998

Simple approach to dosage adjustment in patients with renal impairment.
McCormack JP and Cooper J and Carleton B
PubMed: 9359960
11/1997

A simpler approach to pharmacokinetic dosage adjustments.
McCormack JP and Carleton B
PubMed: 9399625
1997

Drug and poison information resources on the Internet, Part 2: Identification and evaluation.
Marra CA and Carleton BC and Lynd LD and Marra F and McDougal AR and Chow D and McKerrow R
PubMed: 8888076
1996

Overview of health-related quality-of-life measures for pediatric patients: application in the assessment of pharmacotherapeutic and pharmacoeconomic outcomes.
Marra CA and Levine M and McKerrow R and Carleton BC
PubMed: 8888083
1996

Drug and poison information resources on the Internet, Part 1: An introduction.
Marra CA and Lynd LD and McKerrow R and Carleton BC
PubMed: 8840360
1996

Comment: cost of rhDNase in cystic fibrosis.
Marra CA and Carleton BC and Basmadjian D and Levine M and McKerrow R
PubMed: 8845550
10/1995

Spurious rise in total carbon dioxide and chloride with negative anion gap after cystogram.
Abdel-Wareth LO and Lirenman DS and Halstead AC and McLellan D and Carleton BC
DOI: 10.1007/BF02254207
PubMed: 7632530
06/1995

Effects of three immunosuppressive drug protocols on cadaver renal transplantation costs after 4 years of therapy.
Canafax DM and Carleton BC and Matas AJ and Payne WD and Dunn DL and Sutherland DE and Najarian JS
PubMed: 8442239
02/1993

Method for evaluating drip-rate accuracy of intravenous flow-regulating devices.
Carleton BC and Cipolle RJ and Larson SD and Canafax DM
PubMed: 1746576
11/1991

Reversed-phase high-performance liquid chromatographic approach to determine total lymphocyte concentrations of 6-thioguanine, methylmercaptopurine and methylthioguanine in humans.
Erdmann GR and Steury JC and Carleton BC and Stafford RJ and Bostrom BC and Canafax DM
PubMed: 1810943
11/1991

Interaction between cyclosporine and fluconazole in renal allograft recipients.
Canafax DM and Graves NM and Hilligoss DM and Carleton BC and Gardner MJ and Matas AJ
PubMed: 2031258
05/1991

Increased cyclosporine levels as a result of simultaneous fluconazole and cyclosporine therapy in renal transplant recipients: a double-blind, randomized pharmacokinetic and safety study.
Canafax DM and Graves NM and Hilligoss DM and Carleton BC and Gardner MJ and Matas AJ
PubMed: 1989149
02/1991

Research

Genomic and Outcomes Databank for Pharmacogenomic and Implementation Studies (GO PGx)
This Genome Canada project will reduce adverse drug reactions (ADRs) by developing genomic-based precision health strategies and technologies for the most common and severe ADRs in pediatric oncology and facilitate the implementation of pharmacogenomics into clinical practice. This will be realized through four parallel and complementary research activities that will result in genomic-based precision health deliverables for unique end-users:
1. Establish an ADR database of linked clinical and genomic data to discover and validate biomarkers of five severe ADRs associated with cancer therapy drugs in children.
2. Knowledge translation (KT) to facilitate the use of pharmacogenomics in pediatric oncology through the development of clinical practice guidelines and an educational program.
3. Implement ADR-predictive pharmacogenomics tests at 10 pediatric oncology centres across Canada
4. Exploration of how pharmacogenomics testing in pediatric oncology impacts, and is impacted by patients, families, clinicians, and the Canadian healthcare system (GE3LS).

Integrating pediatric pharmacogenomic testing into the Canadian health care system
This project is focused on developing pharmacogenomic tests to predict the risk of experiencing an adverse drug reaction (ADR) in pediatric patients, and strives to bridge the gap between the rigorous science of pharmacogenomics and its integration into health care by providing a tool for the clinical uptake of rigorously derived pharmacogenomic information. To bridge this gap, we have identified actionable pharmacogenomic biomarkers for the most frequently prescribed medication classes and associated ADRs in children: antibiotics, analgesics, and mental health medications. These pharmacogenomic biomarkers all have a compelling rationale for inclusion and were based upon recommendations from FDA and/or Health Canada, Clinical Practice Guidelines, or discovery and replication of research findings in at least three independent populations. Using these robust genomic findings, we will develop three pharmacogenomic panels that possess high analytical validity as well as clinical utility. This product will therefore make the proven benefits of pharmacogenomics accessible to all pediatric patients and their clinicians and pharmacists in Canada. The availability of such tests would provide huge advantages to the thousands of children receiving these frequently prescribed medications every year and will significantly decrease the prevalence of severe and debilitating ADRs related to the most commonly prescribed medications in children.

Grants

DSEN-SEARCH: active Surveillance and Evaluation of Adverse Reactions in Canadian Healthcare – CIHR (2011-2014)

The Canadian Pharmacogenomics Network for Drug Safety - Canada Foundation for Innovation/ Canadian Institutes for Health Research (2008-2013)

DSEN-PREVENT: Pharmacogenomics of Adverse Reactions EVEnts Nation-wide Team – CIHR (2011-2014)

Pharmacogenomics of Warfarin Safety and Effectiveness in Children – CIHR (2012-2013)

Honours & Awards

2011 Canadian Society of Pharmacology and Therapeutics (CSPT) Senior Investigator Award

2009 Award for Clinical Research, CIHR Institute of Human Development, Child and Youth Health (IHDCYH) for the Best Research Poster: Effectiveness of inhaled corticosteroids in preventing morbidity and mortality in individuals with chronic obstructive pulmonary disease and the impact of coexisting asthma. Presented at the IHDCYH Scientific Forum, Winnipeg Manitoba, May 2009.

2008 Awards for Clinical Research, Canadian Association of Paediatric Health Centres (CAPHC) and McMaster University Child Health Research Institute for the Best Research Poster: Genotypic Approaches to Therapy in Children: A National ADR Surveillance Network to Study and Prevent Severe Adverse Drug Reactions in Children. Presented at the CAPHC Annual meeting, Edmonton Alberta, October 2008.

Research Group Members

Tessa Bendyshe-Walton, Graduate Student
Agnieszka Biala, Clinical Research Coordinator
Kathy Wan-Chun Chang, Postdoctoral Research Fellow
Angie Dhanda, UBC Work Learn Student
Britt Drogemoller, Post Doctoral Fellow
Tina-Marie Dryden, Executive Assistant
Gabriella Groeneweg, Program Manager
Erandika Prasadani Gunaretnam, Research Technician
Rohan Kakkar
Philip Khayat, Clinical Pharmacology Consultant
Marije Klumpers, Visiting Scholar:
Tan Le, Work Learn Student
Kathy Li, Statistical Analyst
Jennifer Lin, Masters Student
Cody Lo
Catrina Loucks, Postdoctoral Fellow
Mary Jo Lozano, Research Assistant
Alice Man, UBC Work Learn Student
Caroline Murray, Research Assistant
Nienke Op't Hoog, Visiting Student
Tom Ouellette, UBC Work Learn Student
Miki Tanoshima, Research Assistant
Reo Tanoshima, Research Associate
Tan Toan Le
Jessica Trueman, Research Coordinator
Galen Wright, Research Associate
Kevin Yan, PhD Student
Derek Yau, Finance Coordinator